[Principles of the pathogenetic therapy of congenital extrapyramidal diseases].
D000293:Adolescent; D000328:Adult; D001285:Atropine / Q000627:therapeutic use; D001480:Basal Ganglia Diseases / Q000151:congenital / Q000188:drug therapy; D002614:Chelating Agents / Q000627:therapeutic use; D002908:Chronic Disease; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use; D005260:Female; D006527:Hepatolenticular Degeneration / Q000151:congenital / Q000188:drug therapy*; D006801:Humans; D006948:Hyperkinesis / Q000188:drug therapy; D008297:Male; D006211:Pantothenate Kinase-Associated Neurodegeneration / Q000188:drug therapy; D010300:Parkinson Disease / Q000188:drug therapy; D010396:Penicillamine / Q000627:therapeutic use; D010640:Phenothiazines / Q000627:therapeutic use; D011736:Pyridoxine / Q000627:therapeutic use; D013438:Sulfhydryl Compounds / Q000627:therapeutic use; D014268:Trifluoperazine / Q000627:therapeutic use; D014326:Tropanes / Q000627:therapeutic use
D002614:Chelating Agents; D010640:Phenothiazines; D013438:Sulfhydryl Compounds; D014326:Tropanes; D014268:Trifluoperazine; D004295:Dihydroxyphenylalanine; D001285:Atropine; D010396:Penicillamine; D011736:Pyridoxine
Printsipy patogeneticheskoi terapii nasledstvennykh ekstrapiramidnykh zabolevanii.